Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 6, 2012, Pages 537-542

  Barney, Brandon M ^a   Olivier, Kenneth R ^a   Macdonald, O Kenneth ^a   Fong De Los Santos, Luis E ^a   Miller, Robert C ^a   Haddock, Michael G ^a  

^a MAYO CLINIC   (United States)

Author keywords

clinical outcomes; dosimetric constraints; gastrointestinal tumors; radiotherapy; stereotactic body radiotherapy

Indexed keywords

ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; COLON; DOSIMETRY; DUODENUM; DUODENUM PERFORATION; FEMALE; FOLLOW UP; FOUR DIMENSIONAL COMPUTED TOMOGRAPHY; HUMAN; LIVER; LYMPH NODE; MALE; METASTASIS; OUTCOME ASSESSMENT; PELVIS TUMOR; RADIATION INJURY; SMALL INTESTINE; STEREOTACTIC BODY RADIATION THERAPY; STOMACH; TREATMENT FAILURE; TREATMENT PLANNING;

ADENOCARCINOMA; ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; DOSE FRACTIONATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASMS; ORGANS AT RISK; PANCREATIC NEOPLASMS; RADIOSURGERY; RETROSPECTIVE STUDIES; SPLENIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84870248856     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31821f876a     Document Type: Article

References (39)

1. Abdalla EK, Pisters PW. Metastasectomy for limited metastases from soft tissue sarcoma. Curr Treat Options Oncol. 2002;3:497-505.
2. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280:1485-1489. (Pubitemid 28507400)
3. Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from colorectal cancers: An update. J Hepatobiliary Pancreat Surg. 2008;15:570-580.
4. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45:787-795. (Pubitemid 44423123)
5. Fritz P, Kraus HJ, Muhlnickel W, et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol. 2006;1:30.
6. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2:S94-S100. (Pubitemid 47183602)
7. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable earlystage lung cancer. J Clin Oncol. 2006;24:4833-4839. (Pubitemid 46630909)
8. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117-125. (Pubitemid 44175645)
9. Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486-493.
10. Herfarth KK, Debus J, Lohr F, et al. Stereotactic single-dose radiation therapy of liver tumors: Results of a phase I/II trial. J Clin Oncol. 2001;19:164-170. (Pubitemid 32063493)
11. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823-830. (Pubitemid 44423128)
12. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585-1591.
13. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multiinstitutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572-1578.
14. Schefter TE, Kavanagh BD, Timmerman RD, et al. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005;62:1371-1378. (Pubitemid 40982057)
15. Wulf J, Hadinger U, Oppitz U, et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001;177:645-655. (Pubitemid 34015341)
16. Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861-870.
17. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115:665-672.
18. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48-53. (Pubitemid 41096514)
19. Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010;94:47-52.
20. Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys. 2009;75:71-75.
21. Katoh N, Onimaru R, Sakuhara Y, et al. Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol. 2008;87: 418-424.
22. Choi CW, Cho CK, Yoo SY, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys. 2009;74:147-153.
23. Jereczek-Fossa BA, Fariselli L, Beltramo G, et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol. 2009;93:14-17.
24. Inoue T, Katoh N, Aoyama H, et al. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions. Jpn J Clin Oncol. 2010;40:788-794.
25. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112: 650-658. (Pubitemid 351186206)
26. Murphy JD, Dieterich S, Chang D, et al. Duodenal toxicity in single-fraction stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75:S29-S30.
27. Macdonald OK, Kruse JJ, Miller JM, et al. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: A comparative dosimetric analysis. Int J Radiat Oncol Biol Phys. 2009;75:950-958.
28. National Cancer Institute: COMMON Terminology Criteria for Adverse Events Version 3.0. Bethesda, MD 2006.
29. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
31. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63:320-323. (Pubitemid 41317146)
32. Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys. 2010;76:S101-S107.
33. Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008;18:240-243.
34. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10-S19.
35. Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: A case series and review of the literature. Ann Oncol. 2008;19:577-582. (Pubitemid 351325682)
36. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544. (Pubitemid 46733080)
37. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
38. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. (Pubitemid 36910021)
39. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: Incidence, etiology, and management. Curr Surg. 2006;63:334-337. (Pubitemid 44340939)